cisplatin + filgrastim + ifosfamide + mesna

This is a chemotherapy combination regimen that includes cisplatin (a platinum-based chemotherapy agent), ifosfamide (an alkylating agent), mesna (a uroprotective agent), and filgrastim (a granulocyte colony-stimulating factor or G-CSF). The combination is used in various cancer treatments, particularly for testicular cancer, sarcomas, and other solid tumors. ## Dosing and Administration The regimen typically involves: - Cisplatin: Doses range from 20-75 mg/m² depending on the protocol, administered intravenously - Ifosfamide: Usually 1200-2000 mg/m² daily for 3-5 days, administered intravenously - Mesna: Given as uroprotection to prevent hemorrhagic cystitis from ifosfamide, typically administered before, during, and after ifosfamide infusion - Filgrastim (G-CSF): Started after chemotherapy completion to support neutrophil recovery and prevent severe neutropenia Treatment cycles are typically repeated every 21-28 days, with the exact schedule depending on the specific protocol and cancer type being treated[1][2][4][5]. ## Clinical Applications This combination has been studied and used for: - Testicular germ cell tumors (as part of TIP regimen when paclitaxel is included)[4] - Malignant mixed mesodermal tumors of the ovary[1] - Non-small cell lung cancer[2][7] - Sarcomas[6] - Small cell lung cancer (as part of VIP regimen when etoposide is included)[7] ## Efficacy and Outcomes The efficacy varies by cancer type: - In malignant mixed mesodermal tumors of the ovary: 78% complete response rate and 11% partial response rate were observed in one study, with median progression-free survival of 10 months[1] - In non-small cell lung cancer: Response rates around 27% have been reported[2] - In testicular cancer: When used as part of the TIP regimen (with paclitaxel), it has shown effectiveness as both first-line and salvage therapy[4] ## Toxicity Profile The main toxicities associated with this regimen include: - Hematological toxicity: Severe neutropenia and thrombocytopenia are common and often dose-limiting[1][2] - Renal toxicity: Primarily associated with cisplatin[5] - Hemorrhagic cystitis: Risk from ifosfamide, which is mitigated by mesna[6][10] - Nausea and vomiting[6] - Neurotoxicity: Less common but reported[6] Filgrastim (G-CSF) is included specifically to manage neutropenia and allow for maintenance of dose intensity[2][5]. This combination represents an intensive chemotherapy approach typically reserved for aggressive cancers or salvage therapy settings where the potential benefits outweigh the significant toxicity risks.